Ireland Asthma Treatment Market, By Treatment (Long Term Medications, Quick Relief Medications), By Route of Administration (Injectable, Oral, Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), By Region, Competition, Forecast and Opportunities 2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIreland Asthma Treatment Market, By Treatment (Long Term Medications, Quick Relief Medications), By Route of Administration (Injectable, Oral, Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), By Region, Competition, Forecast and Opportunities 2028
For instance, according to Center for Disease Control and Prevention (CDC), during the coronavirus pandemic, individuals suffering from moderate to severe asthma were at a greater risk of falling ill with acute respiratory disease.
Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, which results in recurring episodes of wheezing, coughing, shortness of breath, and chest tightness. It is a common condition that affects the lungs and can vary in severity from mild to severe. For some people, it became a major concern and causes difficulty in their daily activities and could result in life threatening asthma attack, which is also known as asthma exacerbation. When a person with asthma is exposed to certain triggers, such as allergens (dust mites, pollen, pet dander), respiratory infections, irritants (smoke, strong odors, air pollution), exercise, or changes in weather, the airways become inflamed. This inflammation causes the muscles surrounding the airways to tighten and the lining of the airways to produce excess mucus, leading to the characteristic symptoms of asthma.
According to National Institute of Health, the prevalence of the four main categories of chronic diseases among adults in Ireland has been estimated to be 9.4% for asthma, 9.8% for Chronic obstructive pulmonary disease (COPD), 5.2% for diabetes, and 4.3% for Cardiovascular (CVD)
Additionally, the manufacturers in the asthma treatment market are introducing new therapies and products that reduces the prevalence of life-threatening or uncontrolled asthma attack in patients. Asthma is one of the most common non-communicable diseases in children, and its prevalence varies across countries. For instance, International Study of Asthma and Allergies in Childhood (ISAAC), using a simple and inexpensive standardized methodology, has provided valuable data on the prevalence of the symptoms of childhood asthma and allergies for international comparison from countries with different socio-economic backgrounds.
Furthermore, the ongoing research and development of technology in the development of therapy for asthma treatment is expected to aid the growth of the Ireland asthma treatment market in the forecast period, 2024-2028. Moreover, the government also supports the idea by increasing investment in the pharmaceutical sector and the pharmaceutical companies to enforce manufacturers for taking interest in research and development of advanced therapies in Ireland to bolster the growth of Ireland asthma treatment market.
Rising Prevalence of Chronic Diseases
For instance, according to WHO, asthma affected about 262 million people and 455,000 people succumbed to the disease in 2019. Majority of asthma related deaths occur in low and lower middle-income countries where underdiagnosis and undertreatment are common
Additionally, the increasing number of diagnosed cases and awareness of asthma contribute to the demand for effective treatment options.
Furthermore, a higher prevalence of asthma in the population directly translates to an increased demand for asthma treatment. As more individuals are diagnosed with asthma, the need for effective treatment options rises. This creates a larger market for pharmaceutical companies and healthcare providers to cater to. With a higher prevalence of asthma, there is an increased focus on improving treatment accessibility. Healthcare providers and professionals are more likely to prioritize asthma management programs, ensuring that patients have access to appropriate medications, healthcare services, and education. This accessibility drives the growth of Ireland asthma treatment market.
Increasing Air Pollution Triggering Asthma Cases
. For instance, according to research, the air pollution from traffic, nitrogen dioxide, and second-hand smoking (SHS) are all substantial risk factors for the development of asthma in children
Download Free Sample Report
Recent Developments
In March 2023, a company namely Astra Zeneca Pharmaceuticals Ltd, Amgen’s Asthma had launched Tezspire picks up backing from England’s Nice. Tezspire won approvals in the U.K. and Europe in September 2022. The asthma biologic won an FDA endorsement in late 2021. TEZSPIRE proactively helps reduce inflammation in patients with severe asthma which provides better breathing with improved lung function.
In April 2020, EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union for Enerzair breezhaler, a new asthma treatment which includes an optional digital sensor. This is the first asthma triple combination therapy; it consists of a fixed dose combination of three active substances (indacaterol, glycopyrronium and mometasone furoate) in capsules, to be administered using an inhaler. An optional electronic sensor may also be co-packed with the product. The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. The sensor will send the data to an app on a smart phone or other suitable device.
In July 2020, Novartis AG today announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year. Once-daily Enerzair Breezhaler is the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination found at in the EU for asthma patients.
Market Segmentation
The Ireland asthma treatment market is segmented by treatment, route of administration, distribution channel, regional distribution, and competitional landscape. Based on treatment, the market is further bifurcated into long term medications and quick relief medications. Based on route of administration, the market is bifurcated into injectable, oral, and inhaled. Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies & drug retailers, and online pharmacies.
Market Players
AstraZeneca Pharmaceuticals Ireland, Fresenius Kabi Ireland, GlaxoSmithKline Ireland, Teva Pharmaceuticals Ireland Limited, Novartis Ireland Limited, Sanofi Aventis Ireland Ltd, Hoffmann-La Roche Ireland Limited, Regeneron Ireland, and Merck & Co. Ireland Limited are some of the leading companies operating in the Ireland asthma treatment market.
| Attribute | Details |
| Base Year | 2022 |
| Historical Years | 2018 – 2022 |
| Estimated Year | 2022E |
| Forecast Period | 2023F – 2028F |
| Quantitative Units | Revenue in USD Million, Volume in Units, and CAGR for 2017-2021 and 2022E-2028F |
| Report Coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Treatment Route of Administration Distribution Channel Region Company |
| Region Scope | Northern Ireland, North-West, West, Midland East, Dublin, Shannon, South-East, Cork-Kerry |
| Key Companies Profiled | AstraZeneca Pharmaceuticals Ireland, Fresenius Kabi Ireland, GlaxoSmithKline Ireland, Teva Pharmaceuticals Ireland Limited, Novartis Ireland Limited, Sanofi Aventis Ireland Ltd, Hoffmann-La Roche Ireland Limited, Regeneron Ireland, Merck & Co. Ireland Limited |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy